Success Metrics

Completion Rate

0%(0/1)

Active Trials

2(67%)

Terminated

1(33%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Terminated(1)

Detailed Status

Recruiting1

Terminated1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

recruiting133%

terminated133%

active_not_recruiting133%

Recent Activity

2 active trials

Showing 3 of 3

recruitingphase_1

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

NCT07560865

active_not_recruitingphase_1

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT06342986

terminatedphase_1

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05395052

Clinical Trials (3)

Showing 3 of 3 trials

NCT07560865Phase 1

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

Recruiting

NCT06342986Phase 1

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Active Not Recruiting

NCT05395052Phase 1

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3